These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21254886)

  • 1. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
    Martin S; Feldman SR; Augustin M; Szapary P; Schenkel B
    J Dermatolog Treat; 2011 Jun; 22(3):138-43. PubMed ID: 21254886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
    Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
    Villacorta R; Hay JW; Messali A
    Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
    Wang SH; Chi CC; Hu S
    Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
    Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
    J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficiency of biologic agents in the treatment of moderate to severe psoriasis].
    Blasco AJ; Lázaro P; Ferrándiz C; García-Díez A; Liso J
    Actas Dermosifiliogr; 2009 Nov; 100(9):792-803. PubMed ID: 19889301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.
    de Portu S; Del Giglio M; Altomare G; Arcangeli F; Berardesca E; Calzavara-Pinton P; Lotti T; Martini P; Peserico A; Simonacci M; Vena GA; Girolomoni G
    Dermatol Ther; 2010; 23 Suppl 1():S7-13. PubMed ID: 20136921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
    Farhi D
    Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
    Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
    J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis.
    Schmitt-Rau K; Rosenbach T; Radtke MA; Augustin M
    Dermatology; 2010; 221(3):236-42. PubMed ID: 20924159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.